Synthesis, X-ray structure and strong in vitro cytotoxicity of novel
 organoruthenium complexes by Mojić, Marija et al.
lable at ScienceDirect
Journal of Organometallic Chemistry 749 (2014) 142e149Contents lists avaiJournal of Organometallic Chemistry
journal homepage: www.elsevier .com/locate/ jorganchemSynthesis, X-ray structure and strong in vitro cytotoxicity of novel
organoruthenium complexes
Marija Mojic a,1, Aleksandar Savic b,1, Vladimir B. Arion c, Mirna Bulatovic a,
Jelena M. Poljarevic b, Djordje Miljkovic a, Tibor J. Sabo b, Sanja Mijatovic a,
Danijela Maksimovic-Ivanic a,1, Sanja Grguric-Sipka b,*,1
aDepartment of Immunology, Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Bulevar Despota Stefana 142,
11060 Belgrade, Serbia
b Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, Serbia
c Institute of Inorganic Chemistry, University of Vienna, Währinger Strasse 42, A-1090 Vienna, Austriaa r t i c l e i n f o
Article history:
Received 5 July 2013
Received in revised form
19 August 2013
Accepted 22 August 2013
Keywords:
Apoptosis
Cancer
Organoruthenium
Amine ligands* Corresponding author. Studentski trg 12-16, 1100
113336736; fax: þ381 112184330.
E-mail addresses: sanjag@chem.bg.ac.rs, sanja.grg
Sipka).
1 These authors equally contributed to this work.
0022-328X/$ e see front matter  2013 Elsevier B.V.
http://dx.doi.org/10.1016/j.jorganchem.2013.08.041a b s t r a c t
Two p-cymene ruthenium chlorido complexes containing isobutyl (C1) and isoamyl (C2) esters of (S,S)-
ethylenediamine-N,N0-di-2-(3-cyclohexyl)propanoic acid as ligands were prepared from p-cymene
ruthenium dichloride dimer and corresponding ester. All compounds have been characterized by
elemental analysis, IR, ESI-MS, 1H and 13C NMR spectroscopy. Single crystal X-ray structure diffraction
analysis of C1 shows the usual piano-stool geometry of complexes, with coordination of ester ligand via
nitrogen donor atoms. Ligands exhibit moderate anticancer activity (IC50 > 50 mM), while the complexes
were signiﬁcantly more cytotoxic towards various cancer cell lines, including B16, A375, HCT116, A549
and MCF7 cells (IC50 min.emax. 2.9e8.0 mM). We stress that cisplatin resistant HCT116 cell line was
highly sensitive to the treatment with C1 and C2 (IC50 values: 4.4 and 5.5 mM versus IC50 > 120 mM for
cisplatin). In parallel, primary ﬁbroblasts-MRC-5 were remarkably less affected by these compounds.
 2013 Elsevier B.V. All rights reserved.1. Introduction
Cisplatin is still one of the most frequently used anticancer
drugs [1]. It is mainly used in the treatment of ovarian, head and
neck, bladder, cervical and lymphomas cancers [2]. However, there
are some major drawbacks in the application of this drug: the ef-
ﬁciency for a limited range of cancers, severe side-effects, acquired
or intrinsic resistance [3,4].
In the last years, complexes with metal ions other than plat-
inum, e.g., gallium and ruthenium, have been investigated for their
anticancer properties [5,6]. These compounds have a general lower
toxicity and some of them (KP46, KP1019, NAMI-A) entered clinical
trials with promising results [7,8].
During the last decade, the ﬁeld of ruthenium arene complexes
has received considerable attention as anticancer agents, due to0 Beograd, Serbia. Tel.: þ381
uric@gmail.com (S. Grguric-
All rights reserved.their physicochemical properties that include chemical stability
and structural diversity. Organoruthenium complexes of the type
[(h6-arene)RuII(XY)Z]þ (where XY is a chelating ligand, and Z is
monoanionic ligand) are highly cytotoxic and in vivo reduce tumor
growth. Hydrolysis of RueZ bond may be important step in the
mechanism of cytotoxic action. The rate of hydrolysis of the RueZ
bond is highly dependent on the nature of Z, if this group is labile, it
can assure a faster hydrolysis and coordination site for bio-
molecules [9e11]. The arene ligand stabilizes the metal in its lower
oxidation state and provides a hydrophobic face for the passive
transport inside the cell [12e14]. The arene ligands are strongly
coordinated to the ruthenium center and relatively inert towards
substitution reactions. The three remaining coordination sites
opposite to the p-ligand can be occupied with a wide variety of
mono- or bidentate ligands with N-, O-, S- or P-donor atoms [15].
Unlike platinum(II) complexes which exhibit cytotoxicity by bind-
ing to DNA (in particular to the N7 atom of adjacent guanines), the
mode of action of ruthenium anticancer drugs is still unclear
[16,17]. Complexes bearing N,N0-chelating ligands have shown
cytotoxicity comparable to that of cisplatin in a number of cell lines
[18,19]. These ligands contain nitrogen atoms and are capable of
stabilizing þ2 oxidation state of ruthenium [20]. Structure activity
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gands is established according to numerous in vitro test, against a
panel of various cancer cell lines [21,22]. This class of compounds
includes different esters of (S,S)-ethylenediamine-N,N0-di-2-(3-
cyclohexyl)propanoic acid. These compounds showed a distinct
anti-tumor activity, with ethyl ester being the most active [23,24].
In this work, we describe the preparation, characterization
and in vitro anticancer activity of the ruthenium(II) arene com-
plexes with new esters of (S,S)-ethylenediamine-N,N0-di-2-(3-
cyclohexyl)propanoic acid. The results presented herein reveal
the strong antitumor activity of these complexes, even in cell lines
resistant to conventional cisplatin. Particularly interesting is the
fact that these ruthenium complexes are very active towards a
variety of cell lines, while the ligands themselves do not
show signiﬁcant biological activity. Apoptosis as a type of pro-
grammed cell death induced by these complexes represents a
major mechanism of their action.2. Material and methods
2.1. Chemistry
RuCl3$3H2O was purchased from Johnson Matthey (London,
United Kingdom). (S)-2-Amino-3-cyclohexyl-propanoic acid hy-
drochloride was purchased from Senn Chemicals (Dielsdorf,
Switzerland). [(h6-p-cymene)RuCl2]2 [25] and (S,S)-ethylenedi-
amine-N,N0-di-2-(3-cyclohexyl)propanoic acid dihydrochloride
[23] were prepared according to a published procedure, while
corresponding esters were obtained as described in this paper.
Solvents were obtained from commercial sources and used without
further puriﬁcation. Elemental analysis was carried out with
Elemental Vario EL III microanalyzer. Infrared spectra were recor-
ded on a Nicolet 6700 FT-IR spectrometer using ATR technique. The
NMR spectra were recorded on a Bruker Avance III 500 spectrom-
eter. Mass spectra were measured with a 6210 Time-of-Flight LC-
MS instrument (G1969A, Agilent Technologies) by using DMSO/
H2O for ligands and acetonitrile as solvent for complexes. Electronic
spectra of 1  103 M solutions of organometallic compounds in
acetonitrile were recorded on a GBC UV/Vis Cintra 6 spectropho-
tometer. Melting points were determined on an Electrothermal
melting point apparatus.2.2. Biology
2.2.1. Reagents and cells
Fetal calf serum (FCS), RPMI-1640, phosphate-buffered saline
(PBS), dimethyl sulfoxide (DMSO), and propidium iodide (PI) were
obtained from Sigma (St. Louis, MO). AnnexinV-FITC (AnnV) was
from Biotium (Hayward, CA). ZVAD was from Promega (Madison,
USA) while Apostat was bought from R&D (R&D Systems, Minne-
apolis, MN USA) (Minneapolis, USA). The B16 murine melanoma
was a kind gift fromDr. Sinisa Radulovic (Institute for Oncology and
Radiology of Serbia, Belgrade, Serbia). Human melanoma A375 and
colon cancer HCT116 were a kind gift from Prof. Ferdinando Nic-
oletti (Department of Biomedical Sciences, University of Catania,
Italy). Human lung carcinoma A549, breast adenocarcinoma MCF7
and normal lung ﬁbroblast cell line MRC5 were purchased from
ATCC. Cells are routinely kept in HEPES-buffered RPMI-1640 me-
dium supplemented with 10% FCS, 2 mM L-glutamine, 0.01% so-
dium pyruvate, and antibiotics (culture medium) at 37 C in a
humidiﬁed atmosphere with 5% CO2. After standard trypsinization,
cells were seeded at 1  104/well in 96-well plates for viability
determination and 2.5  105/well in 6-well plate for ﬂow
cytometry.2.2.2. Determination of cell viability by crystal violet assay
The viability of adherent cells was evaluated with crystal violet
(CV) assay [26,27]. Complexes were dissolved in DMSO (stock so-
lutions 200 mM) and ligands in absolute ethanol (stock solutions
18 mM) and then serial dilutions were made in culture medium.
Cells were treatedwith thewide range of doses of the drugs for 24 h
and then cells were ﬁxed with methanol 10 min at RT. In parallel,
control cells were exposed to the same amount of solvents corre-
sponding to their content in the solutions of complexes or ligands.
After ﬁxation cells were stained with 1% crystal violet solution for
15 min, washed, dried and the dye was dissolved in 33% acetic acid.
The absorbance of dissolved dye was measured at 540 nmwith the
reference wavelength at 640 nm. Results are presented as per-
centage of control that was arbitrarily set to 100%.
2.2.3. Cell cycle analysis
Cells were treated with IC50 dose of C1 or C2 for 24 h, then
trypsinized and ﬁxed in 70% ethanol at 4 C overnight. After
washing in PBS, cells were stained with PI (20 mg/ml) and RNase
(0.1 mg/ml) for 30 min at 37 C in the dark. Red ﬂuorescence was
analyzed with FACS Calibur ﬂow cytometer (BD, Heidelberg, Ger-
many). The distribution of cells in different cell cycle phases was
determined with Cell Quest Pro software (BD) [26,28].
2.2.4. AnnexinV-FITC/PI staining and caspase detection
Cells were treated with IC50 dose of C1 or C2 for 24 h, then
trypsinized and stained with AnnV-FITC/PI (Biotium, Hayward, CA)
or apostat according to the manufacturer’s instruction. Cells were
analyzed with FACS Calibur ﬂow cytometer (BD, Heidelberg, Ger-
many) using Cell Quest Pro software (BD) [29,30].
2.2.5. PI staining on chamber slide
Cells were treated with IC50 dose of C1 or C2 for 24 h, and then
ﬁxed in 4% PFA 15 min at room temperature. Cells were stained
2 min with 20 mg/ml PI covered with ﬂuorescent mounting media
(Dako, Glostrup, Denmark) and analyzed under the ﬂuorescent
microscope. Between all steps cells were washed 2e3 times with
PBS [30,31].
2.2.6. Statistical analysis
The results are presented as mean  SD of triplicate observa-
tions from the representative of three experiments, except if indi-
cated otherwise. The signiﬁcance of the difference between
treatments and control was analyzed by ANOVA followed by Stu-
denteNewmaneKeuls test. P < 0.05 was considered signiﬁcant.
3. Results
3.1. Synthesis of the ligands
3.1.1. Synthesis of O,O0-diisobuthyl-(S,S)-ethylenediamine-N,N0-di-
2-(3-cyclohexyl)propanoate dihydrochloride, L1$2HCl
Into the ice-cooled absolute isobutanol (15 mL) the thionyl
chloride (2.00 mL) and (S,S)-ethylenediamine-N,N0-di-2-(3-
cyclohexyl)propanoic acid dihydrochloride (1.20 g, 2.70 mmol)
were added. After 1 h of stirring at 0 C, suspensionwas reﬂuxed for
16 h. The resulting mixture was ﬁltered and left to crystallize. The
white product was ﬁltered off, washed with isobutanol and dried in
vacuo. Compound L1 is a white powder. Yield: 810 mg (53.79%);
Mp: 220 C; 1H NMR (500.26 MHz, TFA-d1): d ¼ 1.19e1.27 (m,
(CH3)2CHCH2e, 12H; C5, 4H), 1.38e1.52 (m, C6, 4H; C7, 2H), 1.77 (m,
C4, 2H), 1.88e2.05 (m, C5,6, 8H; C7, 2H), 2.19 (m, eCH2Cy, 4H;
(CH3)2CHCH2e, 2H), 4.12 and 4.18 (eNH2CH2CH2NH2e, 4H), 4.32
and 4.37 (m, eCH2OOCe, 4H), 4.53 ppm (t, eOOCCHNH2e, 2H); 13C
NMR (125.79 MHz, TFA-d1): 19.58 ((CH3)2CHCH2e), 27.51 and 27.63
Table 1
Crystal data and details of data collection for [(h6-p-cymene)Ru(L1)Cl]
[PF6] (C1).
Empirical formula C38H66ClF6N2O4PRu
Fw 896.42
Space group P1
a [A] 10.2886(5)
b [A] 14.9911(7)
c [A] 15.7340(7)
a [] 63.685(2)
b [] 83.782(3)
g [] 76.489(3)
V [A3] 2115.05(17)
Z 2
l [A] 0.71073
rcalcd [g cm-3] 1.408
Crystal size [mm3] 0.12  0.08  0.04
T [K] 100(2)
m [mm1] 0.538
R1
a 0.0509
wR2
b 0.1211
GOFc 1.050
a R1 ¼ SjjFoj  jFcjj/SjFoj.
b wR2 ¼ f
P½ðF2o  F2c Þ2=
P½wðF2o Þ2g1=2.
c GOF ¼ fP½ðF2o  F2c Þ2=ðn pÞg1=2; where n is the number of re-
ﬂections and p is the total number of parameters reﬁned.
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46.66 (eNH2CH2CH2NH2e), 62.81 (eOOCCHNH2e), 77.25 (e
CH2OOCe), 172.92 ppm (C1); IR (ATR): ~n ¼ 2928.8, 2844.6, 2592.0,
2529.9, 2415.4, 2356.4, 2216.6, 1742.7, 1540.6, 1471.9, 1452.8, 1219.4,
1180.2, 1066.5, 999.1, 807.1 cm1; MS (LC-ESI): m/z (%): 481.40
(26.83) [Me 2HClþ H]þ; Anal. Calcd. for C28H54Cl2N2O4, %: C 60.76,
H 9.76, N 5.06. Found, %: C 60.29, H 9.87, N 4.81.
3.1.2. Synthesis of O,O0-diisoamyl-(S,S)-ethylenediamine-N,N0-di-2-
(3-cyclohexyl)propanoate dihydrochloride, L2$2HCl
O,O0-diisoamyl-(S,S)-ethylenediamine-N,N0-di-2-(3-cyclohexyl)
propanoate dihydrochloride, was prepared as described above, but
using absolute isoamyl alcohol, instead of isobutanol. Compound L2
is a white powder. Yield: 890 mg (56.34%); Mp: 224 C; 1H NMR
(500.26 MHz, TFA-d1): d ¼ 1.16e1.28 (m, (CH3)2CHCH2CH2e, 12H;
C5, 4H; (CH3)2CHCH2CH2e, 2H), 1.39e1.50 (m, C6, 4H; C7, 2H),
1.76e2.05 (m, C4, 2H; C5, C6, 8H; C7, 2H; ((CH3)2CHCH2CH2e), 4H);
2.18 (m, eCH2Cy, 4H); 4.14 and 4.19 (m, eNH2CH2CH2NH2e, 4H),
4.53 and 4.58 (m, eCH2OOCe, 4H), 4.67 ppm (m, eOOCCHNH2e,
2H); 13C NMR (125.79 MHz, TFA-d1): 11.76 and 17.02
((CH3)2CHCH2CH2e), 22.92 ((CH3)2CHCH2CH2e), 27.24 and 27.65
(C7, C6), 35.00 (C4), 36.30 (C5), 38.83 ((CH3)2CHCH2CH2e), 39.62 (e
CH2Cy), 46.63 (eNH2CH2CH2NH2e), 62.84 (eOOCCHNH2e), 70.0 (e
CH2OOCe), 172.84 ppm (C1); IR (ATR): ~n ¼ 2962.4, 2928.2, 2849.9,
2704.9, 2611.6, 2528.5, 2470.1, 2408.6, 2220.1,1746.4,1539.3,1481.4,
1455.5, 1320.5, 1259.4, 1211.3, 1176.5, 1072.7, 998.1, 947.7, 805 cm1;
MS (LC-ESI): m/z (%): 509.43 (6.82) [M e 2HCl þ H]þ; Anal. Calcd.
for C30H58Cl2N2O4, %: C 61.94, H 10.05, N 4.82. Found, %: C 61.54, H
10.21, N 4.79.
3.2. Synthesis of organometallic complexes
3.2.1. Synthesis of [(h6-p-cymene)Ru(L1)Cl], C1
A suspension of ligand O,O0-diisobutyl-(S,S)-ethylenediamine-
N,N0-di-2-(3-cyclohexyl)propanoate dihydrochloride (0.11 g,
0.20 mmol) in methanol (5 mL) priorly neutralized with the
lithium hydroxide monohydrate (16.78 mg, 0.40 mmol), was
added in the mixture of methanol/chloroform (10 mL, 1:1) so-
lution of [(h6-p-cymene)RuCl2]2 (61.23 mg, 0.10 mmol). The re-
action mixture was stirred at 40 C for 3 h. The orange solution
was concentrated under reduced pressure to ca. 10 mL and solid
NH4PF6 (57.05 mg, 0.35 mmol) was added. The mixture was
stirred at room temperature for 1 h and a yelloweorange product
was precipitated. This was ﬁltered off, washed with methanol
and dried in vacuo. Yield: 92 mg (51.31%). Crystals suitable for X-
ray crystallographic study were obtained from mother liquor at
4 C. Mp: 182 C; 1H NMR (500.26 MHz, DMSO-d6): d ¼ 0.90 and
0.98 (d, (CH3)2CHCH2Oe, 12H); 1.10 (m, C5, C6, 8H; C7, 2H), 1.24
(dd, (CH3)2CH(arene), 6H)), 1.55e1.96 and 2.18 (m, C4, 2H; C5, C6,
8H; C7, 2H; eCH2Cy, 4H; eNHCH2CH2NHe, 4H), 2.25 (s, CH3(ar-
ene), 3H), 2.57 (m, (CH3)2CHCH2Oe, 2H), 2.82 (sept, eCH(CH3)2,
1H), 3.91 and 4.03 (m, d (CH3)2CHCH2OOCe, 4H), 3.65 and 4.17
(td, eOOCCHNHe, 2H), 5.08 (d, C12H(arene), 1H), 5.36 (d,
C13H(arene), 1H), 5.81 (d, C120H(arene), 1H), 6.05 (d,
C130H(arene), 1H), 6.82 and 7.05 ppm (td, m, eCH2NHNHCH2e,
2H); 13C NMR (125.79 MHz, DMSO-d6): d ¼ 16.04 (CH3(arene)),
18.79 ((CH3)2CHCH2Oe), 21.52 (eCH(CH3)2), 25.31 (C7), 25.74
(C6), 27.05 ((CH3)2CHCH2Oe), 30.38 (eCH(CH3)2), 31.36 (C5),
34.08 (C4), 37.89 (eCH2Cy), 45.96 and 50.12 (eNHCH2CH2NHe),
58.82 and 60.33 (eOOCCHNHe), 70.90 (CH3)2CHCH2OOC, 74.36
and 75.41 (C12H(arene), C120H(arene)), 85.69 and 86.35
(C13H(arene), C130H(arene)), 92.29 (C14(arene)), 111.82 (C11(ar-
ene)), 171.85 and 173.12 ppm ((CH3)2CHCH2OOCe); IR (ATR):
~n ¼ 3253.9, 2926.8, 2852.8, 1730.7, 1469.9, 1450.0, 1383.7, 1189.4,
839.6 cm1; UV/Vis (CH3CN): lmax (ε) ¼ 325.96 (107), 411.06 nm(67 L mol1 cm1); MS (LC-ESI): m/z (%): 751.38 (100) [M]þ,
752.38 (50.31) [M þ H]þ; Anal. Calcd. for C38H66ClF6N2O4PRu, %:
C 50.91, H 7.42, N 3.13. Found, %: C 50.85, H 7.21, N 3.17.
3.2.2. Synthesis of [(h6-p-cymene)Ru(L2)Cl], C2
A suspension of ligand O,O0-diisoamyl-(S,S)-ethylenediamine-
N,N0-di-2-(3-cyclohexyl)propanoate dihydrochloride (0.13 g,
0.22 mmol) in methanol (5 mL) priorly neutralized with the lithium
hydroxide monohydrate (18.46 mg, 0.44 mmol), was added to the
mixture of methanol/chloroform (10 mL, 1:1) solution of [(h6-p-
cymene)RuCl2]2 (67.35 mg, 0.11 mmol). The reaction mixture was
stirred at 40 C for 3 h. Then the orange solution was concentrated
under reduced pressure to ca. 10 mL. After addition of NH4PF6
(62.75 mg, 0.38 mmol) the ﬁne yellow-orange solid was isolated as
described for complex C1. Yield: 114 mg (62.85%); Mp: 184 C; 1H
NMR (500.26 MHz, DMSO-d6): d ¼ 0.78e1.38 (dt, (CH3)2CHCH2
CH2OOCe, 12H; m, C5, C6, 8H; C7, 2H; (CH3)2CHCH2CH2OOCe, 4H;
dd, (CH3)2CH(arene), 6H), 1.54e1.95 and 2.19 (m, C4, 2H; C5, C6, 8H;
C7, 2H;eCH2Cy, 4H;eNHCH2CH2NHe, 4H), 2.25 (s, CH3(arene), 3H),
2.56 (m, (CH3)2CHCH2OOCe, 2H), 2.81 (sept, eCH(CH3)2, 1H), 3.64
and 4.07 (m, eOOCCHNHe, 2H), 4.18 and 4.29 (m,
(CH3)2CHCH2CH2OOCe, 4H), 5.05 (d, C12H(arene), 1H), 5.35 (d,
C13H(arene), 1H), 5.80 (d, C120H(arene), 1H), 6.07 (d, C130H(arene),
1H), 6.83 and 7.03 ppm (m, eCH2NHNHCH2e, 2H); 13C NMR
(125.79 MHz, DMSO-d6): d ¼ 13.83 and 20.81 ((CH3)2CHCH2CH2
OOCe), 16.01 (CH3(arene)), 21.77 (eCH(CH3)2), 22.05 ((CH3)2CHCH2
CH2OOCe), 25.37 (C7), 25.77 (C6), 27.66 ((CH3)2CHCH2CH2OOCe),
30.46 (eCH(CH3)2), 31.39 (C4), 34.27 (C5), 37.91 (eCH2Cy), 45.91 and
50.13 (eNHCH2CH2NHe), 58.83 and 60.39 (eOOCCHNHe), 64.75
and 65.01 ((CH3)2CHCH2CH2OOCe), 74.15 and 75.28 (C12H(arene),
C120H(arene)), 86.16 and 86.78 (C13H(arene), C130H(arene)), 92.13
(C14(arene)), 112.05 (C11(arene)), 171.88 and 173.01 ppm
((CH3)2CHCH2CH2OOCe); IR (ATR): ~n ¼ 3433.7, 3261.0, 2927.7,
2853.8, 1732.9, 1451.4, 1349.0, 1213.2, 1189.0, 1040.0, 987.5, 961.3,
843.9, 558.6 cm1; UV/Vis (CH3CN): lmax (ε) ¼ 333.62 (86),
412.77 nm (58 L mol1 cm1); MS (LC-ESI): m/z (%): 779.41 (100)
[M]þ, 780.41 (50.80) [M þ H]þ; Anal. Calcd. for C40H70ClF6N2O4PRu,
%: C 51.97, H 7.63, N 3.03. Found, %: C 51.81, H 7.41, N 2.98.
Fig. 2. Ru(II) complexes C1 and C2.
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X-ray diffraction measurements were performed on a Bruker X8
APEXII CCD diffractometer. Single crystal was positioned at 40 mm
from the detector, and 1935 frames were measured, each for 40 s
over 1 scan width. The data were processed using SAINT software
[32] Crystal data, data collection parameters, and structure reﬁne-
ment details are given in Table 1. The structure was solved by direct
methods and reﬁned by full-matrix least-squares techniques.
Nonhydrogen atoms were reﬁned with anisotropic displacement
parameters, except those involved in the observed disorder (vide
infra). Hydrogen atoms were inserted in calculated positions and
reﬁned with a riding model. Two cyclohexane rings and one ester
function in the second complex cation were found to be disordered
over two positions with s.o.f. 0.6:0.4, 0.5:0.5 and 0.5:0.5, respec-
tively. The disorder was resolved by using SADI and EADP tools
implemented in SHELXL. The following computer programs and
hardware were used: structure solution, SHELXS-97 and reﬁne-
ment, SHELXL-97 [33]; molecular diagrams, ORTEP [34] computer,
Intel CoreDuo.
4. Discussion
4.1. Synthesis of ligands and complexes
Isobutyl and isoamyl ester of (S,S)-ethylenediamine-N,N0-di-2-
(3-cyclohexyl)propanoic acid (Fig. 1) have been obtained by the
reaction of acid, corresponding absolute alcohol and thionyl chlo-
ride under reﬂux. The compounds are soluble in triﬂuoroacetic
acid, absolute ethanol and poorly soluble in DMSO.
By exploring the m-chlorido-bridge splitting reaction of [(h6-p-
cymene)RuCl2]2 with L1$2HCl and/or L2$2HCl in methanol/chlo-
roform at 40 C, with subsequent addition of ammonium hexa-
ﬂuorophosphate, complexes [(h6-p-cymene)Ru(L1)Cl] (C1) and
[(h6-p-cymene)Ru(L2)Cl] (C2) (Fig. 2) have been prepared in good
yields. The complexes are soluble in DMSO and insoluble in water.
4.2. Spectroscopic studies
Characteristic absorption bands for aliphatic esters and C]O
stretching vibrations were found in the IR spectra of the ligands
(1743 and 1746 cm1) (Fig. S1) and complexes (1731 and
1733 cm1). Absorption bands due to C]O stretching vibrations in
the complexes show the same wave number as in the free ligands,
indicating non-involvement of those groups into coordination. TheFig. 1. Synthesized ligands L1 and L2.IR spectra of complexes show characteristic absorption bands for
val(NeH) vibrations at 3254 and 3261 cm1. The 1H NMR spectra of
complexes showed characteristic resonances of h6-p-cymene and
the diamine moiety. Upon complexation to the metal, the sym-
metry of the ligand environment is lowered. In the spectra of
complexes this is manifested by the non equivalence of the
chemically equivalent protons in free ligands, e(ROOC)CHeNHe
CH2eCH2eNHeCH(COOR)e. This is also observed in the cymene
ring protons which appear as four doublets, in contrast to the one
signal seen in the [(h6-p-cymene)RuCl2]2. In both cases this is
induced by lower symmetry of the coordination environment.
Signals of eHNeCH2eCH2eNHe in complexes are shifted to lowerFig. 3. A view of one crystallographically independent complex cation [(h6-p-cymene)
Ru(L1)Cl]þ of C1. Selected bond distances (A), bond angles and torsion angles (): Ru1e
Cl1 2.3888(18), Ru1eN1 2.209(5), Ru1eN2 2.206(5), Ru1eC29 2.203(7), Ru1eC30
2.188(6), Ru1eC31 2.169(7), Ru1eC32 2.224(7), Ru1eC33 2.211(6), Ru1eC34 2.155(7);
N1eRu1eN2 81.26(18); QN1eC1eC2eN2 ¼ 59.5(7).
Table 2
IC50 [mM] values of C1 and C2 after 24 h of action against selected tumor cell lines.
IC50 values were calculated as mean  SD from three independent experiments.
Compound B16 A375 IC50 (mM)
HCT116
A549 MCF7 MRC5
C1 5.5  0.9 2.9  1.1 4.4  0.4 6.4  2.5 5.0  0.1 8.7  0.4
C2 7.4  3.2 3.5  1.6 5.5  0.9 8.0  0.3 7.8  0.6 12.0  3.4
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at 2.81 ppm is assigned to one proton from isopropyl group of ar-
omatic ligand. In the 1H NMR spectra of ligands (recorded in TFA,
Fig. S2), NH protons could not be detected, because of the fast ex-
change of these protons with solvent protons. In the 1H NMR
spectra of ligands (recorded in DMSO), NH protons were seen at
9.8 ppm. A lowered symmetry of the coordination environment
was also evidenced by the 13C NMR spectra, particularly for e
(ROOC)CHeNHeCH2eCH2eNHeCH(COOR)e, the cymene ring
carbons and carbonyl groups. The cymene carbons appear as six
signals, unlike four signals in starting ruthenium cymene complex.
Signals of eHNeCH2eCH2eNHe in complexes are downﬁeld shif-
ted in comparison with free ligand.
The mass spectra of the ligands contain peaks assigned to the
[M e 2HCl þ H]þ ion, which is in agreement with their calculated
molecular mass. Parent ions of complexes were detectable m/z at
751 for C1 and m/z 779 (Fig. S3) for C2 and they are in accordance
with expected values.Fig. 4. The effect of C1 and C2 on viability of normal and colon cancer cells. MRC-5
ﬁbroblasts and HCT116 colon cancer cells (1  104) were treated with different doses
of C1 and C2 for 24 h, after which cell viability was measured by CV assay. The data are
presented as mean  SD from representative of three independent experiments.4.3. X-ray studies
The result of X-ray diffraction study of complex C1 is shown in
Fig. 3 with selected bond distances and bond angles given in the
caption. The complex crystallized in the triclinic non-
centrosymmetric space group P1 with two complex cations [(h6-p-
cymene)Ru(L1)Cl]þ and two counteranions [PF6] in the unit cell.
Each ruthenium atom adopts a typical “piano-stool” conﬁguration
with one chlorido ligand and two nitrogen donors of the organic
ligand as the three legs. Both sp3 hybridized nitrogen atoms are
chiral with the same chirality S. Upon binding of the bidentate
ligand to ruthenium a ﬁve-membered chelate ring is formed. A
twist conformation of this metallocycle is adopted in the complex
cation shown in Fig. 3, while an envelope one in the second cation.4.4. Anticancer activity
To explore the anticancer potential of both ligands, L1 and L2
and complexes C1 and C2 several cell lines with different origin and
well deﬁned cell speciﬁcity were selected. Cells were exposed to a
wide range of tested drug doses and cell viability was estimated
after 24 h incubation time. In parallel, cells were treated with li-
gands L1 and L2 in the same dose range. Results clearly indicate
that both complexes possess a strong anticancer potential in vitro
(Table 2). Determined IC50 doses were even lower than previously
found upon the treatment of different adherent cell lines with
rutheniumecymene complexes with cyclohexyl-functionalized
ethylendiamine-N,N0-diacetate-type ligands or cisplatin [35]. On
the other hand, highest dose of the ligand compounds showed only
slight decrease of the cell viability (10e40%) (Table 3).Table 3
Viability of cell lines upon the treatment with 50 mM L1 and L2. Values are expresses as
Compound B16 A375 HCT116
L1 101.0  1.2 97.3  1.5 96.5  1
L2 71.5  4.1 78.9  0.3 81.9  1Given that the new synthesized complexes differ only in the
ester part, compared to the previously synthesized complexes of
this type, a very good biological activity of these complexes was
expected. In parallel, primary ﬁbroblasts-MRC-5 were remarkably
less affected by these compounds, revealing selective potential of
novel drugs against malignant cells (Fig. 4). Importantly, colon
cancer cells HCT116 (IC50 > 120 mM) resistant to one of the most
potent anticancer drug cisplatinwere highly sensitive tomentioned
compounds [30]. Low IC50 doses as well as the ability to overcome
cisplatin developed resistance present one of the greatest advan-
tages of newly created compounds in comparison to commercially
used metal based drugs in oncotherapy [36].
4.5. Cell cycle arrest and apoptosis
Cisplatin resistant cells HCT116 were selected for further ex-
periments. To elucidate the mechanism involved in antitumor% of control and calculated as mean  SD from three independent experiments.
A549 MCF7 MRC5
.8 100.5  1.9 102.7  4.8 93.4  2.1
.0 84.7  3.15 60.6  3.1 52.0  4.1
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each compound and cell cycle distributionwas determined after 24
and 48 h. Remarkable arrest of cells in G0/G1 phase accompanied
by an increased percentage of cells in subG phase was observed
after ﬁrst 24 h (Fig. 5). In addition, progressive accumulation of cells
in G2/M phase as well as hypodiploid cells for approximately 20%
was evident in cultures exposed to C1 or C2 after additional 24 h of
incubation (data not shown). Decreased number of viable cells asFig. 5. The effect of C1 and C2 on cell cycle distribution. HCT116 cells (2  105/well) were e
evaluated. For determination of nuclear morphology cells were stain with PI and analyzedwell as apoptotic nuclei was visualized by PI staining at this time
point (Fig. 5, right panel).
One of the ﬁrst signs of apoptosis is externalization of phos-
phatidylserine residues [37]. At the intracellular level, death signal
will be delivered most often with caspase activation, but in some
cases it will be completed evenwithout functional caspases [38]. To
conﬁrm the hypothesis that novel drugs triggered classic apoptotic
process, cells were exposed to C1 or C2 and after 24 h Ann/PI doublexposed to IC50 doses of C1 and C2 for 24 h and cell cycle distribution (left panel) was
by ﬂuorescent microscopy (right panel).
Fig. 6. The effect of C1 and C2 on apoptotic process. HCT116 cells (2  105/well) were exposed to IC50 doses of C1 and C2 and Ann/PI double staining (A) and ApoStat staining (B)
after 24 h were done.
M. Mojic et al. / Journal of Organometallic Chemistry 749 (2014) 142e149148staining was performed. As displayed in Fig. 6 (upper panel), it is
evident that tested compounds promoted strong apoptotic process
with remarkable accumulation of cells with early apoptotic proﬁle
(AnnþPI) as well as double positive, necrotic cells. In parallel,
apostat staining revealed distinct population of cells with elevated
caspase activity upon the treatment with C1 and C2 for 24 h (Fig. 6,
lower panel).
The obtained data are in accord with our previous results on
rutheniumecymene complexes with cyclohexyl-functionalized
ethylendiamine-N,N0-diacetate-type ligands [35]. In brief, Rue
cymene complex with butyl ester as ligand, induced typical
apoptosis with both phosphatidyl internalization and DNA frag-
mentation accompanied by caspase activation in HL-60 cells con-
ﬁrming that induction of apoptotic process is a unique feature of
these classes of metalo-drugs. However, in the majority of cells
caspase activity was not changed. In line with this, treatment of C1
or C2 with caspase inhibitor ZVAD restores the viability of
approximately 8%. Taken together, apoptosis triggered by both
tested compounds is just partly regulated by caspases. This impli-
cated the advantage of novel compounds to promote death even
independently of caspase activation. In addition, this type of cas-
pase independent apoptosis eliminated undesirable effects of cas-
pase activation, such as signal for compensatory proliferation [39].
5. Conclusion
The ruthenium(II) arene complexes containing new alkyl esters
of (S,S)-ethylenediamine-N,N0-di-2-(3-cyclohexyl)propanoic acid
as chelating ligand have been synthesized. Ligands and complexes
were characterized by NMR, IR spectroscopy and ESI-MS spec-
trometry and the structure of C1 was determined by X-ray
diffraction. The cytotoxic studies showed that the synthesized
complexes exhibited strong biological activity. IC50 values of the
tested complexes were even 10e30 times lower than those of theligand counterparts or even cisplatin under same experimental
conditions. It is noteworthy, that the investigated complexes are
particularly active towards cisplatin resistant HCT116 cell line. Cell
cycle arrest and apoptosis are responsible for cytotoxicity of these
complexes. Of particular interest and importance is the examina-
tion of the anticancer activity of these compounds in vivo, which
will be the subject of future research.
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